BTK and central nervous system cancer: Given the relevance and frequency of ATRX mutations in high-grade glioma patients, we sought to validate the effect of BTK, STAT3, and RTK inhibitors in glioma cell lines derived from adult malignant glioma (MOG-G-UVW and U-251) and pediatric malignant glioma (SF188) patients.